PixelBiosciences GmbH was founded in Heidelberg, Germany, and set up headquarters in China, as PixelBiosciences (Suzhou) Co., Ltd. The new Modality Enzymatic Convergent Assembly (nMECA) platform technology is intellectual property of PixelBiosciences. We are currently specialized in high-throughput, cost-effective gene editing reagents (CRISPR), antibody-oligonucleotide conjugates, as well as the production and research of long RNA and DNA. These products have broad applications in cutting-edge fields such as drug development for gene editing, spatial biology, proteomics, and advanced biomaterial development.

Our vision is to provide cutting-edge technologies for drug development, empowering scientists to make significant clinical advancements in various areas of study, including infectious diseases, cancer and genetic disease. We are committed to become a prominent global leader in oligonucleotides as new drug modalities and technologies.

Recently, we have established an advanced research and development laboratory, a GMP-level production facility and a fully automated digital production line in Suzhou, China, to ensure full capabilities in research and production. These facilities, coupled with our strong technical support, enables us to deliver products and services of the highest quality that effectively tailor to the diverse needs of our customers. We have an unwavering commitment to continuous innovation, outstanding business practices, and  the establishment of lasting partnerships with our core customers. Through our unwavering dedication and ongoing collaborations, we strive to achieve significant breakthroughs and make remarkable contributions to the field of biotechnology.